瑛泰醫療(01501.HK)擬回購上海翰淩醫療器械合共約5.0%股權
格隆匯2月23日丨瑛泰醫療(01501.HK)宣佈,2024年2月23日,公司、賣方及目標公司上海翰淩醫療器械有限公司訂立回購協議。根據回購協議,公司同意向賣方回購目標公司合共約5.0%股權,其中公司將向懷格瑛泰回購目標公司約3.8%股權及公司將向柯偉先生回購目標公司約1.2%股權。
回購完成後,目標公司將由公司擁有約61.36%權益。
上海翰淩是公司的非全資子公司,致力於心臟瓣膜相關產品的研究及開發。上海翰淩的管線產品包括經導管主動脈瓣膜系統、可擴張血管鞘系統及自定位瓣膜擴張球囊導管。
董事會認為,回購是為了進一步優化上海翰淩的股權結構,更有效地實現公司的發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.